Michael A. Metzger - Dec 13, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Dec 13, 2021
Transactions value $
-$462,276
Form type
4
Date filed
12/15/2021, 04:35 PM
Previous filing
Oct 27, 2021
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $14.7K +2.05K +11.58% $7.20 19.7K Dec 13, 2021 Direct
transaction SNDX Common Stock Sale -$39K -2.05K -10.38% $19.05 17.7K Dec 13, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $221K +34.6K +195.73% $6.38 52.2K Dec 13, 2021 Direct
transaction SNDX Common Stock Sale -$659K -34.6K -66.19% $19.05 17.7K Dec 13, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -2.05K -100% $0.00* 0 Dec 13, 2021 Common Stock 2.05K $7.20 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -34.6K -100% $0.00* 0 Dec 13, 2021 Common Stock 34.6K $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 681,422 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $19.00 to $19.49.
F3 This option is fully vested.